Follow @keithspeights
Recent articles
Why Zynerba Pharmaceuticals Stock Is Crashing Today
Investors appear to be worried about potential safety issues with its cannabinoid gel.
Could Amgen's Latest Bad News Boost the Chances of More Acquisitions?
Amgen's recent clinical setback just might prompt the big biotech to light a fire beneath its acquisition efforts.
These 2 Cannabis Companies Kicked In Over $1 Million to Legalize Pot in Florida. Will Their Bets Pay Off?
Sunny beaches, popular theme parks -- and recreational marijuana? Big bucks are flowing in to make legal pot in Florida a reality.
Could Vaping Concerns Boost the Chances of U.S. Pot Legalization?
Hundreds of mysterious cases of vaping-related illnesses are causing some to advocate that legalizing pot is more important now than ever.
3 Top Stocks You Can Buy and Hold for the Next Decade
Great business models. Great growth prospects. Great moats. These three stocks check off all the boxes for buying and holding for years to come.
Better Buy: Abbott Laboratories vs. Dexcom
Which stock wins in a battle between these two continuous glucose monitoring system leaders?
Better Buy: Illumina vs. Guardant Health
Which stock wins in a matchup between a gene sequencing pioneer and a fast-rising liquid biopsy leader?
3 Top Cannabis Stocks to Buy Now
These cannabis stocks are profitable. They're growing rapidly. And they're great picks to buy right now.
5 Big Unanswered Questions for Aurora Cannabis After Its Q4 Letdown
Forget Aurora's revenue miss in Q4. Here's what investors need to be concerned about going forward.
Better Buy: Celgene vs. Gilead Sciences
Which stock wins in a battle between these two big biotechs?
Why Ardelyx Shares Are Sinking Today
Investors appear to be taking profits off the table after the biotech announced a key FDA approval.
Better Marijuana Stock: Auxly Cannabis Group vs. The Green Organic Dutchman
Which stock wins in a battle between a vertically integrated cannabis company and a fast-rising cannabis producer?
What's Behind Aurora Cannabis' Q4 Miss -- and Why It's Throwing Shade on Canopy Growth
Aurora's executives explain the company's embarrassing Q4 revenue miss and why it's in better shape than its biggest rival.
Why Rite Aid Stock Is Sinking Today
An analyst's negative take is causing a sell-off for the retail pharmacy stock.
3 Large-Cap Healthcare Stocks Recently Hitting All-Time Highs: Are They Buys?
Huge year-to-date gains have propelled these stocks to record highs. But can their sizzling momentum continue?
GW Pharmaceuticals Isn't a Cannabis Stock -- and 4 Other Things Its CEO Wants You to Know
What you'll want to know from GW Pharmaceuticals CEO Justin Gover's comments this week at the Morgan Stanley conference.
Better Marijuana Stock: Aphria vs. Constellation Brands
Which stock wins in a one-on-one matchup between a top Canadian cannabis producer and an alcoholic beverage giant with a big stake in the global cannabis market?
Anxious About AbbVie? Here Are 4 Things You Should Know
The situation for AbbVie probably isn't nearly as bad as you think it is.
Aurora Cannabis' Q4 Shocker: What You Need to Know
Aurora embarrassingly overpromised and underdelivered with its Q4 results. But it's not all bad news.
4 Key Questions for Gilead Sciences' New CEO
What's next for Gilead? CEO Dan O'Day provided some answers this week.